

Curriculum Vitae

Name	Jeong Eun Kim
Current Position & Affiliation	Assistant Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine
Country	South Korea

Educational Background

1999. 3 – 2005. 2	M.D. College of Medicine Pusan National University Busan, Korea
2008. 3 – 2010. 2	Master University of Ulsan College of Medicine Seoul, Korea
2010. 3 – 2012. 2	Ph. D. University of Ulsan College of Medicine Seoul, Korea

Professional Experience

2005. 3 – 2006.2	Internship Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2006.3 – 2010. 2	Residency, Internal Medicine Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2010.3 – 2012.2	Clinical fellow Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea

2012.3 – 2015.2	Clinical Instructor Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2015.3 – 2020.2	Clinical Assistant Professor Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2020.3 –	Associate Professor Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea

Professional Organizations

Member, Korean Medical Association
Member, Korean Society of Internal Medicine
Member, Korean Cancer Study Group
Member, Korean Cancer Association
Member, Korean Society of Medical Oncology
Member, American Society of Clinical Oncology

Main Scientific Publications

1. Bang YH, **Kim JE**, Hong YS et al. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. *Scientific Reports* volume 11, Article number: 7118 (2021)
2. **Kim JE**, Choi J et al. High prevalence of TP53 loss and whole-genome doubling in early- onset colorectal cancer. *Exp Mol Med*. 2021 Mar 22. Online ahead of print.
3. Jeong JH, **Kim JE** et al. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone

- receptor-positive, HER2- negative metastatic breast cancer: The LEO study. *Eur J Ca.* 2021 Feb;144:341-350
4. Jeong HH, Hong YS, **Kim JE** et al. The Role and Clinical Effectiveness of Multiline Chemotherapy in Advanced Desmoplastic Small Round Cell Tumor. *Clin Med Insights Oncol.* 2021 Feb 17;15:1179554920987107
 5. Bang YH, Hong YS, **Kim JE** et al. Effectiveness of combining bevacizumab with first-line chemotherapy regimens for metastatic colorectal cancer in real-world practice. *Clin Col Ca.* 2020 Oct. Epub ahead of print
 6. Cho HY, **Kim JE** et al. Patterns of recurrence in patients with curative resected rectal cancer according to different chemoradiotherapy strategies: Does preoperative chemoradiotherapy lower the risk of peritoneal recurrence? *Oncol Lett.* 2020 Nov;20(5):242
 7. Oh CR, Hong JY, **Kim JE** et al. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. *Target Oncol.* 2020 Aug;15(4):485-493
 8. Kim JH, Kim SY, **Kim JE** et al. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study. *Target Oncol.* 2019 Dec;14(6):689-697.
 9. Hong YS, Kim SY, **Kim JE** et al. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. *J Clin Oncol.* 2019 Nov 20;37(33):3111-3123
 10. **Kim JE**, Chae SY, Kim JH et al. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. *Eur J Nucl Med Mol Imaging.* 2019 Jul;46(8):1713-1722
 11. Chae SY, Kim SB, **Kim JE** et al. Diagnostic accuracy and safety of 16 α -[18F]fluoro-17 β - oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. *Lancet Oncology.* 2019 May;20:4
 12. Moon JH, Hong SW, **Kim JE** et al. Targeting β -catenin overcomes MEK inhibition resistance in colon cancer with *KRAS* and *PIK3CA* mutations. *British journal of Cancer.* 2019.120,941-951
 13. **Kim JE**, Chun SM, Kim TW et al. Mutation burden and I index for Detection of microsatellite instability in colorectal cancer by targeted next-generation sequencing. *Journal of Molecular Diagnostics.* 2019 Mar;21(2):241-250